CFH

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

Retrieved on: 
Monday, March 11, 2024
Health Technology, Technology, Nanotechnology, Pharmaceutical, Oncology, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, WGS, Nephrology, APHP, STR, Single-nucleotide polymorphism, Partnership, CFH, Patient, Chelsea Handler, RUO, HPO, Oxford Nanopore Technologies, Thrombotic microangiopathy, Developed country, Nanopore sequencing, Thrombosis, CNV, Pharmaceutical industry

Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.

Key Points: 
  • Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
  • It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
  • In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
  • “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.

Blackhawk Network (BHN) Partners with Roblox to Expand Launch of Digital Gift Cards

Retrieved on: 
Wednesday, February 14, 2024
Software, Technology, Digital Cash Management, Digital Assets, Payments, Roblox, USD, CFH, BRL, JPY, CHF, Communication, Blackhawk Network Holdings, CAD, Creativity, GBP, BHN, Online shopping

Leading branded payments provider, Blackhawk Network (BHN), has partnered with Roblox, a global immersive platform for communication and connection, to offer Austrian (EUR), Belgian (EUR), Swiss Franc (CFH), and Brazilian Real (BRL) digital gift cards on Roblox’s gift card site, Roblox.com/giftcards .

Key Points: 
  • Leading branded payments provider, Blackhawk Network (BHN), has partnered with Roblox, a global immersive platform for communication and connection, to offer Austrian (EUR), Belgian (EUR), Swiss Franc (CFH), and Brazilian Real (BRL) digital gift cards on Roblox’s gift card site, Roblox.com/giftcards .
  • Consumers in each respective country can now purchase Roblox digital gift cards in their local currencies.
  • Roblox digital gift cards enable users to purchase Robux, the platform’s virtual currency, which is used to acquire digital items and accessories for an enhanced and more personalized experience.
  • This expansion follows the November 2023 announcement from BHN that consumers throughout Japan can now purchase digital Roblox gift cards .

HSBC UK partners with Nova Credit to become first UK bank to offer newcomers option to include international credit history when applying for a credit card

Retrieved on: 
Monday, September 18, 2023
Banking, Personal Finance, Professional Services, QAR, DKK, ICD, CNY, PLN, JPY, SGD, NOK, GBP, CFH, MXN, HSBC UK, Research, SEK, INR, Global Money Week, NZD, AUD, AED, Unsecured guarantor loan, Growth, HSBC, International, SAR, Isle of Man, BHD, CAD, HKD, Isle, HSBC Expat, RUB, THB, Partnership, KWD, TRY, OMR, United Kingdom, International Credit Insurance & Surety Association, United Arab Emirates, Bank, Nursing, Online shopping, Security (finance), CZK, USD, EUR, SKK

“Opening a credit card and building credit is an important step when setting up life in a new country.

Key Points: 
  • “Opening a credit card and building credit is an important step when setting up life in a new country.
  • Access credit faster: leverage credit history built up overseas, using Nova Credit’s Nova Passport technology, to start a positive credit history in the UK on arrival.2
    3.
  • More information on HSBC UK’s international banking services: www.hsbc.co.uk/international/
    Images available: Screenshot of credit card application journey on mobile and image of an HSBC UK credit card.
  • International Credit Decisioning (ICD) has been available from March 2023 in the UK, enabling credit history transfer from 12 countries for HSBC UK credit card applications.

Jones Soda Co. Announces Appointment of David Knight as New President and Chief Executive Officer

Retrieved on: 
Thursday, June 8, 2023
EBay, CFH, PepsiCo, CSE, Drink, University, Foreign Affairs Policy Board, OTCQB, Marketing, Quaker Oats Company, Jones Soda, Internal communications, CBD, Growth, Private investigator, Management

Mr. Knight has a Bachelor of Business, Marketing from the University of New South Wales in Sydney, Australia.

Key Points: 
  • Mr. Knight has a Bachelor of Business, Marketing from the University of New South Wales in Sydney, Australia.
  • I believe Jones is well-positioned for continued growth and I look forward to building on the momentum that Mark has started,” stated Mr. Knight.
  • Mr. Knight will succeed Mark Murray, who while retiring as the Company‘s President and Chief Executive Officer, will continue to remain on the Board as a director.
  • “On behalf of the full Board, I would like to thank Mark for his tireless service to Jones as President and CEO.

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

Retrieved on: 
Monday, April 24, 2023
Fortress Biotech, Perelman School of Medicine at the University of Pennsylvania, CFH, University, Fortification, Cubic foot, Complement, Geographic atrophy, Factor, University of Pennsylvania, GA, AAV, Patient, Ophthalmology, Therapy, Vaccine, Pharmacology

MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

Key Points: 
  • MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.
  • Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones.
  • A range of single-digit royalties on net sales are also payable.
  • Partnering with 4DMT further validates the Fortress business model of identifying and developing promising treatments for patients, while pursuing opportunities that potentially maximize shareholder value.

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

Retrieved on: 
Monday, April 24, 2023
Retina, Injection, Perelman School of Medicine at the University of Pennsylvania, CFH, University, Chelsea Handler, Doctor of Philosophy, Attention deficit hyperactivity disorder predominantly inattentive, AMD, Cubic foot, Inflammation, CMC, Survival, Complement, End organ damage, Factor, University of Pennsylvania, Atypical hemolytic uremic syndrome, GA, AAV, Geographic atrophy, IVT, Patient, Ophthalmology, Therapy, Autoimmunity, Disease, Vaccine, Pharmaceutical industry, R100, Pharmacology

Geographic atrophy is a highly prevalent disease with a significant unmet medical need.

Key Points: 
  • Geographic atrophy is a highly prevalent disease with a significant unmet medical need.
  • According to published estimates, there are over one million individuals with GA in the U.S. alone as of 2022.
  • The first treatment for GA, complement inhibitor pegcetacoplan injection, was approved in the U.S. in February 2023 and is administered by intravitreal (IVT) injection once every 25 to 60 days.
  • Complement Factor H (CFH) is a master regulator of the complement system, functioning as a natural inhibitor of the alternative complement pathway.

medZERO Adds Another FinTECH Award at Meta Lab Challenge

Retrieved on: 
Tuesday, June 7, 2022
Professional Services, Health, Technology, Other Health, Mobile, Wireless, Software, Finance, Metaverse, LendingTree, LG Electronics, EY, Goal, Aircraft, Science and technology in Asia, Electronics, MassChallenge, CEO, Government, Innovation, Association of British HealthTech Industries, CFH, Future, MC, Shared, Health, Acquisition, Connected health, Industry, Learning, Education, Pharmaceutical industry, Health insurance, Management, Silicon

medZERO is a national Mobile lending & healthcare payments platform that makes healthcare affordable for employees struggling to pay their bills.

Key Points: 
  • medZERO is a national Mobile lending & healthcare payments platform that makes healthcare affordable for employees struggling to pay their bills.
  • Businesses and healthcare providers headquartered throughout the Charlotte region have the opportunity to participate in the Meta Lab medZERO program with discounts and rewards available for those who sign up quickly.
  • The goals of the challenge aligned with our mission perfectly, said Craig Froude, medZERO CEO and co-founder.
  • The Meta Lab is a forward-thinking collaboration among Charlottes city leaders in fintech and healthtech to cultivate a world-leading ecosystem for innovation and collaboration.

AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

Retrieved on: 
Wednesday, June 1, 2022
Retina, Severe cognitive impairment, Night vision, ACHM, Eye, Company, Program, Knowledge, Form 10-K, Central nervous system, Annual report, Forward-looking statement, CEO, Disease, Smoking, Applied Genetic Technologies Corporation, AMD, Optogenetics, Nasdaq, Therapy, CFH, AAV, University, University of Nevada, Reno, Coronavirus Scientific Advisory Board (Turkey), Risk, Central nervous system disease, Patient, GLOBE, Complement, Technology, Neurotology, Achromatopsia, COVID-19, Research, SEC, Geographic atrophy, Population, Reading, Factor, SAB, Drug development, CNS, Ageing, Western world, Pharmaceutical industry, Ophthalmology

We look forward to their contributions in support of our effort to develop a treatment for dry AMD.

Key Points: 
  • We look forward to their contributions in support of our effort to develop a treatment for dry AMD.
  • Jeff Heier, a newly appointed member of the SAB, added, I feel privileged to be a part of this distinguished group of clinicians during this exciting time at AGTC.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • Its preclinical programs build on the companys industry leading AAV manufacturing technology and scientific expertise.

Gemini Therapeutics Reports 2021 Financial Results

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Nasdaq, Securities Act of 1933, AMD, Risk, Annual report, U.S. Securities and Exchange Commission, Research, CFH, Patient, Anetoderma, Â, COVID-19, Therapy, SEC, Insurance, Forward-looking statement, File, Pharmaceutical industry

Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
  • Gemini reported a net loss of $71.9 million for the full year 2021 compared to $40.8 million for the same period in 2020.
  • Research and development expenses were $48.7 million and $28.2 million for the twelve months ended December 31, 2021 and 2020, respectively.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Hemp Bioscience Company CFH Releases Its ProLine of Clinical-Strength CBD Wellness Products

Retrieved on: 
Thursday, March 3, 2022
Cream, Skiing, Clinical research, Research, Genetics, Menthol, Inflammation, Pain, Functional medicine, Terpene, Agriculture, Foot, Athlete, Proline, Flavonoid, GLOBE, Cannabinoid, Joint, CFH, Dietary supplement, CBD

Longmont, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Colorado-based hemp bioscience company CFH, Ltd. , launches a Rapid Relief Roll-on Gel and Relief Cream as a part of its ProLine.

Key Points: 
  • Longmont, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Colorado-based hemp bioscience company CFH, Ltd. , launches a Rapid Relief Roll-on Gel and Relief Cream as a part of its ProLine.
  • The CFH ProLine, which debuted as a lineup of professional-grade full-spectrum hemp extract products for clinical use, is now available online nationwide at www.CFH.Ltd .
  • The vertically integrated company controls all aspects of product development to ensure all products are made with the highest quality hemp.
  • Founded in 2014, CFH, Ltd. is Colorado-based, vertically integrated hemp bioscience company and a leading supplier of CBD nationwide.